The process of bringing an FDA medical device to the United States market is not just about choosing the kind of submission to be used. The FDA regulation strategy takes into account the classification of the device, the intended use, claims, technology, data, testing, documentation, quality systems, and post-market requirements.
For manufacturers new to the US market, the first issue is usually clear: what is FDA asking for in this device? The answer varies according to the nature of the device, its intended use, risk profile, technology, predicates, regulatory history, and the evidence available for supporting the claims.
Elexes helps medical device companies assess these factors early, develop a practical FDA regulatory pathway, prepare the supporting documentation, and manage regulatory activities through submission and beyond.
FDA requirements can become difficult to navigate when a device does not fit neatly into an existing regulatory pathway or when several regulatory decisions are connected.
You may need regulatory support when:
⦿ You are unsure how FDA would classify your device or which product code applies.
⦿ You have several potential predicates but are uncertain which one provides an appropriate regulatory basis.
⦿ Your intended use or claims may affect the regulatory pathway.
⦿ The device incorporates software, AI/ML, cybersecurity, wireless technology, or other newer technologies.
⦿ Required performance, clinical, biocompatibility, EMC, electrical safety, human factors, or other evidence has not yet been defined.
⦿ Existing documentation was developed for another market and needs to be assessed for U.S. applicability.
⦿ FDA has raised questions during review.
⦿ A modification to a marketed device may affect its existing FDA authorization.
⦿ Your organization needs to establish or update FDA registration, listing, or related establishment information.
The objective is to identify the regulatory decisions that matter before they create rework later in development or submission preparation.
There is no one-size-fits-all FDA pathway that will work for all kinds of medical devices. There are several pathways under FDA pre-market framework based on different factors including classification, risk, novelty, predicate availability, and other device-specific factors.
The starting point is understanding whether the product meets the FDA definition of a medical device and, if so, how FDA classifies it.
FDA classification is connected to the applicable regulation, medical specialty panel, and product code. The Product Classification Database is one of FDA's tools for identifying these elements.
Elexes can evaluate:
⦿ Definition and status of device
⦿ Regulation of classification
⦿ Code for product
⦿ Classification controls
⦿ Authorized FDA devices
⦿ Preliminary submission requirements
The intended use and proposed claims influence how FDA views a device and the evidence needed to support it.
We review the proposed intended use, indications, patient population, use environment, technological characteristics, and claims together rather than treating labeling as a final-stage exercise.
This helps identify whether the proposed claims are aligned with the intended regulatory pathway and available evidence.
For devices potentially qualifying for 510(k) marketing pathway, the choice of predicate and substantial equivalence approach are key factors. FDA defines substantial equivalence through intended use and technology based on appropriate data.
For novel devices where there is no legally marketed predicate, a De Novo request may be relevant depending on the applicability of statutory criteria.
Elexes analyses regulatory history, predicate options, technological differences, and documentation needs prior to making recommendation on the submission strategy.
The appropriate FDA approach depends on individual device and regulatory situation. In general terms, Elexes performs assessment and preparation of submission in the following premarket pathways and programs.
The 510(k) pathway generally requires a demonstration of substantial equivalence to a legally marketed predicate, unless an applicable exemption or different pathway applies. FDA currently requires most 510(k) submissions to be submitted electronically through eSTAR, subject to applicable exemptions.
The De Novo pathway is used for certain novel, low to moderate risk medical devices that lack a predicate legally marketed in the United States and for which general controls alone, or general and special controls alone, would provide a reasonable assurance of safety and effectiveness.
Premarket Approval is the FDA marketing application pathway for devices requiring PMA, including many Class III devices. It involves scientific and regulatory review of evidence supporting the device's safety and effectiveness.
The Q-Submission Program provides mechanisms for obtaining FDA feedback and holding meetings related to various medical device submissions, including 510(k)s, De Novo requests, PMAs and IDEs.
An IDE can allow an investigational device to be used in a clinical study to collect safety and effectiveness data, subject to the applicable IDE requirements. Significant-risk studies require FDA and IRB approval before initiation.
The Breakthrough Devices Program is available for certain devices meeting FDA's eligibility criteria and can provide opportunities for increased interaction with FDA during development and prioritized review. A designation request is submitted through a Q-Submission.
A regulatory pathway is only one part of the submission strategy. The supporting evidence and documentation must also address the characteristics and risks of the specific device. Depending on the device and pathway, Elexes can support assessment and preparation of:
⦿ Device description and technological characteristics
⦿ Specifications and engineering information
⦿ Intended use and indications
⦿ Accessories and components
⦿ Manufacturing information
⦿ Regulatory history
⦿ Applicable standards and guidance
The evidence strategy is developed according to the device and applicable FDA expectations. Depending on the product, this may include:
⦿ Bench and performance testing
⦿ Electrical safety and EMC
⦿ Biocompatibility
⦿ Sterilization and shelf life
⦿ Software verification and validation
⦿ Human factors and usability
⦿ Cybersecurity
⦿ Animal or clinical evidence where applicable
Current guidance from the FDA includes recommendations on software functions and cybersecurity documentation relevant to pre-market submissions.
FDA regulatory strategy does not end with the premarket submission.
The Quality Management System Regulation (QMSR) became effective on February 2, 2026, amending 21 CFR Part 820 and incorporating ISO 13485:2016 by reference. FDA also transitioned to its updated medical-device inspection process from that date.
This means FDA strategy should consider the relationship between the submission, product development controls, manufacturing activities, and the organization's quality system.
For establishments involved in commercial distribution, FDA registration and device listing requirements may apply. Foreign manufacturers also have U.S. Agent requirements, while importer responsibilities depend on the establishment's role.
Elexes can support:
⦿ Establishment registration and listing assessment
⦿ U.S. Agent coordination where applicable
⦿ Manufacturer/importer role assessment
⦿ QMS readiness considerations
⦿ Submission-to-QMS alignment
⦿ FDA inspection readiness
FDA interaction does not necessarily end when a submission is filed.
During review, FDA may request additional information or clarification. For example, the 510(k) review process can involve interactive review and formal Additional Information requests.
Elexes can support:
⦿ FDA correspondence and interaction
⦿ Responses to FDA questions
⦿ Additional-information responses
⦿ Regulatory position development
⦿ Submission amendments where applicable
⦿ Change-impact assessments
⦿ Post-clearance or post-approval regulatory strategy
⦿ Registration and listing maintenance
⦿ Post-market regulatory obligations
If there is any modification of design, materials, manufacturing process, software, labelling, or intended use for any marketed devices, then such modifications may need regulatory review.
FDA provides certain guidance regarding what kinds of modifications require a new 510(k).
Post-market responsibilities can also include Medical Device Reporting and, where applicable, corrections and removals.
A submission route selected before classification, intended use, claims, and predicate analysis are adequately understood can create downstream rework.
Even though a predicate appears technically identical, it needs to be carefully evaluated from the viewpoint of intended use and technical characteristics.
Testing plans are more useful when they are connected to the device's regulatory pathway, risks, claims, and FDA expectations.
Existing EU, Canadian, Australian, or other market documentation can provide useful source material, but it should not automatically be assumed to satisfy FDA requirements.
Generally, the FDA guidance provides the thinking and recommendations of the agency unless there is any legal or regulatory requirement applicable. Elexes segregates the regulations, FDA guidance, recognized standard and device specific requirements while preparing the regulatory strategy.
Elexes approach FDA projects around the decisions that need to be made and the evidence required to support them.
We review the device, intended use, claims, technology, classification, regulatory history, existing approvals, and available evidence.
We assess potential FDA pathways and identify the regulatory route that should be evaluated based on the device-specific facts.
We establish the evidence, testing, documentation, labeling, risk, software, cybersecurity, clinical, and quality-system considerations relevant to the pathway.
We support regulatory documentation, submission preparation, gap resolution, and consistency across the submission package.
Where included in scope, we support Q-Sub interactions, FDA questions, review correspondence, and responses.
Following authorization, we can support change assessments, registration/listing considerations, post-market requirements, and future regulatory activities.
Elexes can also support organizations pursuing multiple markets by coordinating U.S. regulatory work with broader international RA/QA activities and, where required, helping identify or coordinate an appropriately qualified locally based regulatory resource.
⦿ What FDA classification and product code may apply to our device?
⦿ Which regulatory pathway should we assess?
⦿ Is there an appropriate predicate?
⦿ What evidence and testing should we plan?
⦿ Can our existing international documentation be reused?
⦿ Does our software or cybersecurity profile create additional FDA considerations?
⦿ Are our claims consistent with the proposed pathway?
⦿ What establishment, registration, listing, or U.S. Agent requirements apply?
⦿ How should we respond if FDA raises questions?
⦿ What regulatory assessment is needed when we modify an already marketed device?
A regulatory assessment prior to the heavy investment on testing or submission can go a long way in identifying those decisions and evidences that need to be considered.
Use the FDA Regulatory Readiness Checklist to conduct an initial review of classification, pathway, documentation, evidence, labeling, quality-system, and post-market considerations.
It all begins with the right regulatory strategy even before writing the submission. Elexes can assist you in your device assessment, understanding of the regulatory path, identifying the evidence and documentation requirements.
It depends on the device’s classification, applicable exemptions, intended use, and whether another marketing pathway applies. A device-specific assessment is needed before concluding that a 510(k) is appropriate.
There is potentially a way, but it will need to be evaluated against the FDA requirements and the requirements specific to the particular device.
No, clinical evidence requirements vary according to the particular device, pathway, risk, claim and non-clinical evidence.
Yes, depending on the applicability of the QMSR. The quality system and its controls and records might interact with product development and regulation processes. The QMSR is effective from February 2, 2026.
Yes, depending on the scope of the engagement Elexes can help respond to review comments, additional information requests and other FDA communications.
Our process begins with an in-depth consultation where we learn about your medical device, its intended use, and your specific goals. This helps us tailor our assessment to your unique needs.
Our team of experts is well-versed in global medical device regulations, including FDA submissions, CE marking, TGA requirement, Health Canada approvals, ISO, and more. We stay up-to-date with the latest changes in the regulatory landscape.
We will conduct a comprehensive review of your existing documentation, including design files, clinical data, quality management systems, and risk assessments.
Our consultants will perform a gap analysis to identify any areas where your device may fall short of compliance. This forms the basis for our recommendations.
Based on our findings, we will provide you with detailed recommendations and a roadmap for achieving compliance. This may involve revising documentation, conducting additional testing, or making necessary design changes.
Our services don't stop with just the assessment. We offer ongoing support to guide you through the compliance process, helping you address any challenges that may arise.
Elexes offers a globally recognized ISO 13485 certification consultant who is renowned to enhancing your business credibility in the medical devices industry.
Our presence across the globe ensures audits are conducted by local-language auditors, facilitating clear communication and understanding.
Our experts provide guidance and consultants to help you adhere to necessary regulations, ensuring your products meet all legal requirements and is compliant to all necessary standards.
At Elexes, we offer to assist in securing additional local certifications, enabling you to manufacture and sell medical devices in various markets across the globe.
We offer complete confidentiality to all our clients which makes us one of the most trusted regulatory and quality compliance consulting.
We offer different services that will help you not only keep your product well in boundaries of regulations but also speed up the entire approval process. Some of these services are -
CEO Masterlink, Arizona
CEO Novasignal, Los Angeles
President ViDava, Florida
Sr. Exe Treedental, Hong Kong
Manager Outset Medical, California
CTO Jana Care, Massachusetts
MD Blackrock Pharma, England
VP Regulatory AliveCor, California
Owner Liz Inc., Arizona
CEO Radformation, New York
Never miss out on any important update on the regulatory & compliance industry across the globe. Subscribe to our newsletter now.
Copyright 2025, Elexes Medical Consulting Pvt. Ltd. All Rights Reserved
Working Hours : Monday to Friday 9:00 AM - 7:00 PM
Team Elexes 
